Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 452

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

Open access
Zost, Seth J., Gilchuk, Pavlo, Chen, Rita E., Case, James Brett, Reidy, Joseph X., Trivette, Andrew, Nargi, Rachel S., Sutton, Rachel E., Suryadevara, Naveenchandra, Chen, Elaine C., Binshtein, Elad, Shrihari, Swathi, Ostrowski, Mario, Chu, Helen Y., Didier, Jonathan E., MacRenaris, Keith W., Jones, Taylor, Day, Samuel, Myers, Luke, Eun-Hyung Lee, F., Nguyen, Doan C., Sanz, Ignacio, Martinez, David R., Rothlauf, Paul W., Bloyet, Louis-Marie, Whelan, Sean P. J., Baric, Ralph S., Thackray, Larissa B., Diamond, Michael S., Carnahan, Robert H., Crowe, James E.·2020·Nature Medicine

Published version of a preprint

Abstract

Antibodies are a principal determinant of immunity for most RNA viruses and have promise to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 has caused a global pandemic with millions of infections and hundreds of thousands of deaths to date1,2. In response, we used a rapid antibody discovery platform to isolate hundreds of human monoclonal antibodies (mAbs) against the SARS-CoV-2 spike (S) protein. We stratify these mAbs into five major classes on the basis of their reactivity to subdomains of S protein as well as their cross-reactivity to SARS-CoV. Many of these mAbs inhibit infection of authentic SARS-CoV-2 virus, with most neutralizing mAbs recognizing the receptor-binding domain (RBD) of S. This work defines sites of vulnerability on SARS-CoV-2 S and demonstrates the speed and robustness of advanced antibody discovery platforms. A platform for rapid antibody discovery enabled the isolation of hundreds of human monoclonal antibodies against SARS-CoV-2 and the prioritization of potent antibody candidates for clinical trials in patients with COVID-19.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-020-0998-x

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Research works printed but not linked: 1

  1. Williamson, L. E. et al. Early human B cell response to Ebola virus in four U.S. survivors of infection. J. Virol. 93, e01439-18 (2019). · DOI

Cited by

See all 452

Metadata

Authors
Zost, S. J., Gilchuk, P., Chen, R. E., Case, J. B., Reidy, J. X., Trivette, A., Nargi, R. S., Sutton, R. E., Suryadevara, N., Chen, E. C., Binshtein, E., Shrihari, S., Ostrowski, M., Chu, H. Y., Didier, J. E., MacRenaris, K. W., Jones, T., Day, S., Myers, L., Eun-Hyung Lee, F., Nguyen, D. C., Sanz, I., Martinez, D. R., Rothlauf, P. W., Bloyet, L.-M., Whelan, S. P. J., Baric, R. S., Thackray, L. B., Diamond, M. S., Carnahan, R. H., & Crowe, J. E.
Venue
Nature Medicine
Published
2020-07-10
Volume
26
Issue
9
Pages
1422-1427
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W3040899749
Cited by
452
References
50
FWCI
11.59
Type
journal article
Language
en
Open access
bronze
Licence
Funders
  • United States Department of Defense | Defense Advanced Research Projects Agency (HR0011-18-2-0001)
  • U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (75N93019C0007, 75N93019C00062, T32 AI 095202)
  • U.S. Department of Health & Human Services | NIH | National Center for Research Resources (1S10RR028106, UL1 RR024975-01, UL1 TR000445-06)
  • Merck KGaA | EMD Serono (2019 Future Insight Prize)
  • Vanderbilt University Medical Center (Dolly Parton COVID-19 Research Fund)
  • Helen Hay Whitney Foundation (Postdoctoral Fellowship)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. https://app.cochat.ai/papers/10.1038/s41591-020-0998-x
The paper
Zost, S. J., Gilchuk, P., Chen, R. E., Case, J. B., Reidy, J. X., Trivette, A., Nargi, R. S., Sutton, R. E., Suryadevara, N., Chen, E. C., Binshtein, E., Shrihari, S., Ostrowski, M., Chu, H. Y., Didier, J. E., MacRenaris, K. W., Jones, T., Day, S., Myers, L., . . . Crowe, J. E. (2020). Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nature Medicine. https://doi.org/10.1038/s41591-020-0998-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.